Overview

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study

Status:
Unknown status
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, controlled drug interaction study to determine the effects of darunavir plus ritonavir on the pharmacokinetics of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, in HIV-1-seronegative subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Cincinnati
Treatments:
Darunavir
Ritonavir
Rosuvastatin Calcium